Merck & Co., Inc. (NYSE:MRK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Merck & Co., Inc. (NYSE:MRK) has been assigned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $154.2381.

Several research firms have commented on MRK. JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Guggenheim lifted their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Morgan Stanley raised Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $116.00 to $179.00 in a report on Thursday, August 20th. Finally, Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a research report on Wednesday, August 12th.

Insiders Place Their Bets

In related news, EVP Richard Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the sale, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. This trade represents a 9.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last quarter. 0.17% of the stock is owned by corporate insiders.

Institutional Trading of Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRK. BlackRock Inc. grew its position in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after buying an additional 1,073,507 shares during the period. Wellington Management Group LLP boosted its stake in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the last quarter. Geode Capital Management LLC boosted its stake in Merck & Co., Inc. by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. Norges Bank acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $3,997,933,000. Finally, Bank of America Corp DE grew its holdings in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck outperformed the broader market in the latest session, reflecting continued investor momentum and demand for the pharmaceutical company’s shares. Merck Outperforms Broader Market
• Positive Sentiment: Positive Phase 3 data has helped Merck beat the market in 2026, while its dividend—an annualized payout of approximately $3.40—offers a yield above 2.3%, supporting the stock’s appeal to income-oriented investors. Merck Dividend and Market Performance
• Positive Sentiment: Merck is pursuing opportunities to extend Keytruda-related research through commercial orbital laboratories. Although still experimental, the initiative could create new insights for oncology research if regulatory and logistics hurdles are resolved. Keytruda Space Research
• Positive Sentiment: Analysts and investors are increasingly focused on Merck’s efforts to build a stronger portfolio beyond Keytruda, including its roughly $70 billion pipeline and potential oncology partnerships. Merck’s Pipeline Beyond Keytruda
• Neutral Sentiment: Brokerages have set an average price target of $151.32, implying limited additional upside from recent levels and signaling measured rather than aggressive optimism. Merck Price Target
• Neutral Sentiment: RBC Capital maintained a Hold rating, suggesting the company’s growth prospects are balanced by valuation and execution risks. RBC Maintains Hold Rating
• Neutral Sentiment: Unusually high options volume indicates increased trading interest, but it does not by itself establish a bullish or bearish direction. Merck Options Volume
• Negative Sentiment: Merck’s premium valuation leaves less room for disappointment, while the market remains concerned about the eventual loss of Keytruda exclusivity and whether the pipeline can replace that franchise’s earnings contribution. Merck Pipeline Valuation Analysis

Merck & Co., Inc. Trading Up 1.7%

Shares of NYSE:MRK opened at $147.31 on Friday. The firm has a fifty day moving average of $137.99 and a two-hundred day moving average of $125.05. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $156.92. The firm has a market capitalization of $363.45 billion, a P/E ratio of 117.85, a price-to-earnings-growth ratio of 6.31 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.